Delving into the Latest Updates on MV-130 with Synapse

Overview

Basic Info

Drug Type

Live attenuated vaccine, Prophylactic vaccine

Synonyms

BACTEK-R, Bacmune, Bactek

+ [3]

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication-

Inactive Indication

Bronchial SpasmBronchiolitisCOVID-19+ [1]

Originator Organization

Inmunotek SL

Active Organization

Inmunotek SL

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

A mechanistic clinical trial with the aim to evaluate whether MV130 can induce the expression of a particular immune response (trained immunity) in peripheral blood cells. Therefore, the investigators are not evaluating efficacy in any disease or medical condition but rather assessing the immunological effect in immunogenicity of MV130 in healthy volunteers.

Start Date01 Sep 2023

Sponsor / Collaborator

Inmunotek SL

NCT04452643

/ WithdrawnPhase 3

Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial on the Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to SARS-CoV-2 Infection in Healthcare Personnel

The purpose of this trial is to assess the effect of immunotherapy with the bacterial preparation MV130 on the spread and course of SARS-CoV-2 infection in highly exposed subjets, as is the case with healthcare personnel.

Start Date01 Oct 2020

Sponsor / Collaborator

Inmunotek SL

100 Clinical Results associated with MV-130

Login to view more data

100 Translational Medicine associated with MV-130

Login to view more data

100 Patents (Medical) associated with MV-130

Login to view more data

14

Literatures (Medical) associated with MV-130

01 Apr 2025·Trends in Immunology

Trained immunity-based mucosal immunotherapies for the prevention of respiratory infections

Review

Author: Montalbán-Hernández, Karla ; Iborra, Salvador ; Minute, Luna ; Conejero, Laura ; Bravo-Robles, Laura ; Del Fresno, Carlos

The devastating impact of respiratory infections demonstrates the critical need for novel prophylactic vaccines. In this opinion article, we advocate for bacterial immunotherapies as a complementary tool in our fight against respiratory infections. These immunotherapies can activate a wide spectrum of immunological mechanisms, with trained immunity (TI) being particularly significant. This phenomenon has led to the concept of trained immunity-based vaccines (TIbVs), which represent a novel approach in vaccinology. We discuss examples of TIbVs, including the tuberculosis vaccine Bacille Calmette-Guérin (BCG) and the polybacterial immunotherapy MV130. From our viewpoint, illustrating the mode of action and clinical evidence supports the proposal that TIbVs should be considered as next-generation vaccines to confer protection against a wide range of respiratory infections.

01 Jan 2023·Frontiers in immunology

Combining different bacteria in vaccine formulations enhances the chance for antiviral cross-reactive immunity: a detailed in silico analysis for influenza A virus.

Article

Author: Lafuente, Esther M ; Ras-Carmona, Alvaro ; Reche, Pedro A ; Subiza, Jose L ; Bodas-Pinedo, Andrés ; Pelaez-Prestel, Hector F

Bacteria are well known to provide heterologous immunity against viral infections through various mechanisms including the induction of innate trained immunity and adaptive cross-reactive immunity. Cross-reactive immunity from bacteria to viruses is responsible for long-term protection and yet its role has been downplayed due the difficulty of determining antigen-specific responses. Here, we carried out a systematic evaluation of the potential cross-reactive immunity from selected bacteria known to induce heterologous immunity against various viruses causing recurrent respiratory infections. The bacteria selected in this work were Bacillus Calmette Guerin and those included in the poly-bacterial preparation MV130: Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus epidermidis, Klebisella pneumoniae, Branhamella catarrhalis and Haemophilus influenzae. The virus included influenza A and B viruses, human rhinovirus A, B and C, respiratory syncytial virus A and B and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Through BLAST searches, we first identified the shared peptidome space (identity ≥ 80%, in at least 8 residues) between bacteria and viruses, and subsequently predicted T and B cell epitopes within shared peptides. Interestingly, the potential epitope spaces shared between bacteria in MV130 and viruses are non-overlapping. Hence, combining diverse bacteria can enhance cross-reactive immunity. We next analyzed in detail the cross-reactive T and B cell epitopes between MV130 and influenza A virus. We found that MV130 contains numerous cross-reactive T cell epitopes with high population protection coverage and potentially neutralizing B cell epitopes recognizing hemagglutinin and matrix protein 2. These results contribute to explain the immune enhancing properties of MV130 observed in the clinic against respiratory viral infections.

01 Jan 2022·Cell ReportsQ1 · BIOLOGY

Trained immunity induction by the inactivated mucosal vaccine MV130 protects against experimental viral respiratory infections

Q1 · BIOLOGY

ArticleOA

Author: Nieto, Antonio ; Amores-Iniesta, Joaquín ; Relaño, Carlos ; Del Fresno, Carlos ; Brandi, Paola ; Saz-Leal, Paula ; Ardavín, Carlos ; Dopazo, Ana ; Cueto, Francisco J ; Dunphy, Gillian ; Enamorado, Michel ; Casanovas, Miguel ; Sancho, David ; Quintas, Ana ; Martínez-Cano, Sarai ; Conejero, Laura ; Gómez, Manuel J ; Subiza, José Luis ; Nistal-Villán, Estanislao

MV130 is an inactivated polybacterial mucosal vaccine that confers protection to patients against recurrent respiratory infections, including those of viral etiology. However, its mechanism of action remains poorly understood. Here, we find that intranasal prophylaxis with MV130 modulates the lung immune landscape and provides long-term heterologous protection against viral respiratory infections in mice. Intranasal administration of MV130 provides protection against systemic candidiasis in wild-type and Rag1-deficient mice lacking functional lymphocytes, indicative of innate immune-mediated protection. Moreover, pharmacological inhibition of trained immunity with metformin abrogates the protection conferred by MV130 against influenza A virus respiratory infection. MV130 induces reprogramming of both mouse bone marrow progenitor cells and in vitro human monocytes, promoting an enhanced cytokine production that relies on a metabolic shift. Our results unveil that the mucosal administration of a fully inactivated bacterial vaccine provides protection against viral infections by a mechanism associated with the induction of trained immunity.

100 Deals associated with MV-130

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 3	Dominican Republic	Inmunotek SL	10 Jun 2020
COVID-19	Phase 3	Dominican Republic	Inmunotek SL	10 Jun 2020
Pulmonary Disease, Chronic Obstructive	Phase 3	Spain	Inmunotek SL	01 Apr 2013
Bronchial Spasm	Phase 3	Spain	Inmunotek SL	01 Oct 2012
Bronchiolitis	Phase 3	Spain	Inmunotek SL	01 Oct 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EUCTR2012-003253-28 (ERS2021) Manual	Phase 3	Pulmonary Disease, Chronic Obstructive	198	MV130	anvidburfa(bteohdyech) = pxzsftgkki qwoqtwkkux (hjfjedekda, 1.0 - 3.0) View more	Positive	05 Sep 2021
				Placebo	anvidburfa(bteohdyech) = qkoqxbcjrc qwoqtwkkux (hjfjedekda, 1.0 - 5.0) View more
NCT01734811 (MV130, CTgov)	Phase 3	Bronchiolitis \| Bronchial Spasm	120	Biological vaccine (Placebo)	komlzqqmnu(mhifkazjqy) = dqqldknqtf rndaeyaiyw (akpvriuexy, fesoavxeqi - szkmcelhce) View more	-	04 Sep 2020
				Biological vaccine (Biological Vaccine)	komlzqqmnu(mhifkazjqy) = szukmqnivk rndaeyaiyw (akpvriuexy, rccpdborio - jlnnlclqvp) View more